Low-Dose Naltrexone for Endometriosis-Related Pain
Low-dose naltrexone is not recommended for endometriosis-related chronic pelvic pain because it lacks FDA approval for this indication, is not included in ACOG guidelines, and the highest-quality systematic review from 2024 found it ineffective for chronic pain conditions.
Guideline-Based First-Line Recommendations
The American College of Obstetricians and Gynecologists establishes clear evidence-based treatment priorities for endometriosis-related pain that do not include low-dose naltrexone:
GnRH agonists for ≥3 months or danazol for ≥6 months represent first-line pharmacologic treatment for moderate-to-severe endometriosis pain (ACOG Evidence Level A) 1
Second-line options include oral contraceptives, progestins (oral or depot medroxyprogesterone acetate), and NSAIDs for effective pain control (ACOG Evidence Level B) 1
Surgical excision should be considered when pain persists despite optimal medical therapy, though 44% of patients experience symptom recurrence within one year 1
Why Low-Dose Naltrexone Should Not Be Used
Regulatory Status
Naltrexone is FDA-approved only for opioid dependence (50 mg daily) and alcohol use disorder (50 mg daily), not for pain management 2
The FDA label explicitly states naltrexone doses above 50 mg carry higher hepatocellular injury risk, and the drug must be part of comprehensive addiction management—not pain treatment 2
Evidence Quality
The most recent and highest-quality systematic review (2024) analyzing 7 randomized controlled trials with 406 patients concluded that low-dose naltrexone is NOT effective in managing chronic pain or improving quality of life 3
This 2024 systematic review directly contradicts earlier, lower-quality evidence and represents the strongest available data prioritizing morbidity and quality-of-life outcomes 3
A 2020 systematic review found only 8 heterogeneous studies (4 case reports, 3 clinical studies, 1 RCT) and concluded more large-scale studies are needed due to insufficient evidence 4
Guideline Exclusion
ACOG guidelines explicitly state that dietary supplements and non-standard therapies should NOT replace established medical therapy for endometriosis 1
No current ACOG guidelines include low-dose naltrexone as a recommended treatment option for endometriosis-related pain 1
Clinical Algorithm for Endometriosis Pain Management
Step 1: Initiate GnRH agonists (≥3 months) or danazol (≥6 months) for moderate-to-severe pain 1
Step 2: If inadequate response or contraindications exist, use oral contraceptives, progestins, or NSAIDs 1
Step 3: Consider surgical excision if medical therapy fails, understanding the 44% one-year recurrence rate 1
Step 4: Obtain preoperative imaging (transvaginal ultrasound) before surgery to reduce postoperative morbidity and repeat surgery rates 1
Step 5: Screen for renal impairment, hepatic impairment, and concurrent potassium-sparing agents before prescribing progestins 1
Important Caveats
Retrospective data suggesting benefit: One 2023 retrospective study of 115 patients reported 65% perceived benefit from low-dose naltrexone (most commonly 4.5 mg daily), but this was uncontrolled, relied on subjective reporting, and had 36% discontinuation rates 5
Case reports exist but lack rigor: A 2025 case series of 3 vulvodynia patients (not endometriosis) reported subjective improvement, but case series represent the lowest quality evidence and cannot guide treatment decisions 6
Off-label compounding required: Low-dose naltrexone (1-5 mg) must be compounded by pharmacies, creating access barriers and quality control concerns 7
No fertility data: Current evidence does not demonstrate that any supplement or off-label therapy affects future fertility in women with endometriosis 1
Practical Implementation
When patients request low-dose naltrexone for endometriosis pain:
Redirect to evidence-based therapies: Explain that ACOG guidelines prioritize proven hormonal treatments with demonstrated efficacy in reducing lesion size 1
Address the evidence gap: Share that the 2024 systematic review found low-dose naltrexone ineffective for chronic pain, and no studies specifically evaluate it for endometriosis-related pain 3
Monitor established therapy: If patients are already on standard treatment, optimize dosing and duration before considering any adjunctive interventions 1
Document informed refusal: If patients decline guideline-based therapy, document the discussion of superior evidence-based alternatives 1